Table 4.

Dual-energy x-ray absorptiometry and high-resolution peripheral quantitative computed tomography parameters in the zoledronate and control groups

ParameterControl BaselineControl 12 moChanges,a Absolute/%Zoledronate BaselineZoledronate 12 moChanges,a Absolute/%P Value TransplantP Value Zoledronate versus ControlP Value Interaction
BMD lumbar spine, g/cm20.95±0.130.96±0.130.01/1.050.90±0.140.95±0.130.05/5.6<0.010.630.04
BMD total hip, g/cm20.89±0.14b0.96±0.130.07/7.90.80±0.140.90±0.200.1/12.5<0.0010.550.15
BMD femoral neck, g/cm20.79±0.140.81±0.140.02/2.50.69±0.140.73±0.110.04/5.80.0010.280.03
HR-pQCT tibia
 Tt.vBMD, mg HA/cm3282±48b278±42−4/−1.4239±67236±64−3/−1.30.030.140.35
 Tb.vBMD, mg HA/cm3148±41b144±32−4/−2.7117±32115±33−2/−1.70.040.020.53
 Ct.vBMD, mg HA/cm3895±86898±953/0.3870±101865±95−5/−0.60.550.410.61
 BV/TV, %12.3±3.211.8±2.7−0.5/−4.19.8±2.79.5±2.7−0.3/−3.10.78<0.0010.94
 Tb.N,1/mm1.58±0.251.60±0.290.02/1.31.34±0.321.45±0.400.11/8.20.100.020.38
 Tb.Th, mm0.08±0.010.07±0.01−0.01/−12.50.07±0.010.07±0.010/00.020.480.34
 Tb.Sp, mm0.57±0.11b0.57±0.110/00.72±0.200.69±0.26−0.03/−4.20.200.010.69
 Ct.Th, mm1.20±0.231.19±0.21−0.1/−8.31.02±0.331.03±0.320.1/9.80.980.160.73
 Ct.Po, %5.0±4.25.2±4.30.2/45.0±3.84.8±2.9−0.2/−40.870.910.29
 S, kN/mm222.5±65.7217.7±60.9−7.8/−3.5192.5±63.6189.4±62.6−3.1/−1.60.200.190.78
 F.ult, kN58.8±39.358.1±39.1−0.7/−1.251.5±35.351.0±34.9−0.5/−1.00.880.560.98
HR-pQCT radius
 Tt.vBMD, mg HA/cm3322±69317±69−5/−1.6274±93264±91−10/−3.60.080.070.62
 Tb.vBMD, mg HA/cm3182±55173±48−9/−4.9153±49145±48−8/−5.20.020.140.99
 Ct.vBMD, mg HA/cm3837±121839±1182/0.2799±122798±107−1/−0.10.970.270.86
 BV/TV, %14.6±4.814.8±4.10.2/1.412.8±3.812.1±4.0−0.7/−5.50.010.130.98
 Tb.N, 1/mm1.95±0.402.05±0.290.1/5.11.83±0.371.92±0.350.09/4.90.060.360.80
 Tb.Th, mm0.08±0.020.07±0.01−0.01/−12.50.07±0.020.06±0.02−0.01/−14.20.0010.180.67
 Tb.Sp, mm0.46±0.130.43±0.08−0.03/−6.50.50±0.140.48±0.13−0.02/−40.070.500.68
 Ct.Th, mm0.71±0.220.72±0.220.1/140.61±0.300.60±0.27−0.01/−1.6>0.990.200.69
 Ct.Po, %2.9±2.53.1±2.50.2/6.92.4±1.42.2±1.3−0.2/−8.30.940.320.25
 S, kN/mm87.6±2586.0±25.5−1.6/−1.875.6±33.475.5±28.2−0.1/−0.3>0.990.290.34
 F.ult, kN42.4±14.443.5±13.11.1/2.635.3±12.534.7±10.7−0.6/−1.70.840.310.32
  • Continuous variables are presented as mean ± SD. P values are derived from a linear mixed model. BMD, bone mineral density; HR-pQCT, high-resolution peripheral quantitative computed tomography; Tt.vBMD, total volumetric bone mineral density; HA, hydroxyapatite; Tb.vBMD, trabecular volumetric bone mineral density; Ct.vBMD, cortical volumetric bone mineral density; BV/TV, trabecular bone volume/total volume; Tb.N, number of trabeculae; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; Ct.Th, cortical thickness; Ct.Po, cortical porosity; S, stiffness; F.ult, estimated failure load.

  • a Changes according to groups.

  • b P<0.05 control versus zoledronate at baseline (tested by unpaired t test or Mann–Whitney as appropriate).